Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Clinical Trial Paper

Pulmonary artery thrombi are co-located with opacifications in SARS-CoV2 induced ARDS

Katharina Mueller-Peltzer c, Tobias Krauss c, Matthias Benndorf c, Corinna N. Lang a,b, Fabian Bamberg c, Christoph Bode a,b, Daniel Duerschmied a,b, Dawid L. Staudacher a,b, Viviane Zotzmann a,b,*

a Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany
b Department of Medicine III (Interdisciplinary Internal Medicine Intensive Care), Faculty of Medicine, University of Freiburg, Germany
c Department of Diagnostic and Interventional Radiology, Faculty of Medicine, University of Freiburg, Germany

A R T I C L E I N F O

Keywords:
COVID19
CT-Scan
CTPA
Pulmonary embolism
Pulmonary artery thrombosis
SARS-CoV2

A B S T R A C T

Purpose: Patients hospitalized for infection with SARS-CoV-2 typically present with pneumonia. The respiratory failure is frequently complicated by pulmonary embolism in segmental pulmonary arteries. The distribution of pulmonary embolism in regard to lung parenchymal opacifications has not been investigated yet.

Methods: All patients with COVID-19 treated at a medical intensive care unit between March 8th and April 15th, 2020 undergoing computed tomography pulmonary angiography (CTPA) were included. All CTPA were assessed by two radiologists independently in respect to parenchymal changes and pulmonary embolism on a lung segment basis.

Results: Out of 22 patients with severe COVID-19 treated within the observed time period, 16 (age 60.4 ± 10.2 years, 6 female SAPS2 score 49.2 ± 13.9) underwent CT. A total of 288 lung segment were analyzed. Thrombi were detectable in 9/16 (56.3%) patients, with 4.4 ± 2.9 segments occluded per patient and 40/288 (13.9%) segments affected in the whole cohort. Patients with thrombi had significantly worse segmental opacifications in CT (p < 0.05) and all thrombi were located in opacitated segments. There was no correlation between d-dimer level and number of occluded segmental arteries.

Conclusions: Thrombi in segmental pulmonary arteries are common in COVID-19 and are located in opacitated lung segments. This might suggest local clot formation.

1. Introduction

In hospitalized patients infected with SARS-CoV-2, respiratory failure is a common complication [1]. Since the beginning of the outbreak, multiple studies evaluating imaging techniques described bilateral ground-glass opacities, crazy-paving and air-space consolidations in peripheral and basal distribution in patients with COVID-19 pneumonia [2,3]. Some of these studies have investigated the changes of parenchymal opacifications during the time of infection and the assessment of severity using chest CT-scans [4–6].

Apart from COVID-19 pneumonia, a coagulopathy is reported in a considerable number of patients [7]. Notably, elevated d-dimer levels correlate with poor prognosis in COVID-19 [8]. Several case reports and retrospective analyses report thrombotic complications, most of which are pulmonary embolisms [9,10]. Therefore, the association between SARS-CoV-2 infection and disseminated intravascular coagulation, D-dimer levels, deep vein thrombosis, pulmonary embolisms, and microvascular thrombosis is under investigation [8,9,11]. Interestingly, during the initial SARS-CoV-2 outbreak in China, pulmonary embolisms were not described. One possible explanation is the fact that mostly chest CT scans without contrast medium were used [2–6]. The pathological mechanism causing pulmonary embolism in COVID-19 remains unclear. It has been speculated that endothelial inflammation promotes thrombosis and hypoxic pulmonary vasoconstriction might facilitate local thrombus formation mediated by activation of complement

Abbreviation: BMI, body mass index; CTPA, computed tomography pulmonary angiogram; ECMO, veno-venous extracorporeal membrane oxygenation; GGO, ground-glass opacification; HU, houndsfield units; ICU, intensive care unit; PAPsys, systolic pulmonary arterial pressure; PAT, pulmonary artery thrombi; ROI, region of interest; SAPS2, simplified acute physiology score 2; SD, standard deviation; TISS, therapeutic intervention scoring system.

* Corresponding author. Department of Interdisciplinary Internal Medicine Intensive Care, Hugstetter Str. S5, 79106, Freiburg, Germany.
E-mail address: viviane.zotzmann@universitaets-herzzentrum.de (V. Zotzmann).

https://doi.org/10.1016/j.rmed.2020.106135
Received 12 June 2020; Received in revised form 25 August 2020; Accepted 27 August 2020
Available online 11 September 2020
0954-6111/© 2020 Elsevier Ltd. This article is made available under the Elsevier license (http://www.elsevier.com/open-access/userlicense/1.0/).
pathways and an associated procoagulant state [7,12]. This would require pulmonary artery thrombosis to be formed locally, in areas of active SARS-CoV-2 pneumonia. To our best knowledge, the distribution of pulmonary embolism in regard to lung parenchymal opacifications and normal parenchyma has not been investigated yet.

Therefore, the aim of our study was to investigate if pulmonary embolism manifestations are limited to lung segments affected by COVID-19 pneumonia.

2. Methods

2.1. Study population

In this retrospective study, we included all patients admitted to the medical intensive care unit (ICU) of our hospital with proven SARS-CoV-2 infection between March 8th and April 15th, 2020. During this period of time a total of 22 patients with proven SARS-CoV-2 infection and severe pulmonary failure were admitted to the medical ICU; patients’ electronic medical records and, if available, computed tomography (CT) examinations were reviewed. Patients underwent a contrast enhanced CT with pulmonary angiography when likelihood of pulmonary embolism was considered high. Patients were retrospectively recruited for this study if they fulfilled the following inclusion criteria: 1) Positive test for SARS-CoV-2 infection; 2) contrast enhanced CT with pulmonary angiography.

2.2. CT examination protocol

The hypothesis of our study, that pulmonary artery thrombi would not be present in non-COVID-19 affected lung segments, was made before starting the examination and only this endpoint was evaluated. Pulmonary angiography CT scans were performed using a commercial CT scanner (SOMATOM Definition Flash; Siemens Healthineers GmbH, Forchheim, Germany) with the following scanning parameters: tube voltage, 100 kV; tube current, 90 mAs; rotation time, 0.28 s. 128 × 0.6 mm collimation with automated dose modulation (CARE dose4D, Siemens Healthineers GmbH, Forchheim, Germany).

Images were reconstructed at 1 mm slice thickness with an increment of 0.6 mm with an advanced modeled iterative reconstruction using I26f (mediastinal) and B50f (lung) kernels (Siemens Healthineers GmbH, Forchheim, Germany).

Patients without extracorporeal membrane oxygenation (ECMO) received the standard pulmonary angiography protocol with bolus-tracking method. 70 ml contrast agent (Imeron 400, Bracco Imaging, Germany) followed by a 50 ml bolus saline solution were injected at a flow rate of 4 ml/s using a jugular central venous line. The region of interest (ROI) was placed in the pulmonary trunk. The CT scan started after a threshold of 100 Houndsfield units (HU) was reached within the ROI. To give consideration to an altered blood flow in patients with ECMO device the amount of contrast agent was adjusted to 100 ml and the ROI was placed in the air. The scan was manually started when an adequate contrast was visually detected in the pulmonary trunk. If tolerated by the patient ECMO flow was reduced to 70 to 50% of the initial value after scout acquisition for the time of the contrast enhanced scan.

2.3. Imaging analysis

Two radiologists (KMP, TK) with 6 and 13 years of experience in thoracic radiology assessed the CTPA (computed tomography pulmonary angiography) scans in consensus reading for image quality, parenchymal changes and pulmonary embolism. All scans were viewed in axial and coronal 1 mm slices at standard lung and soft tissue window. Pulmonary artery contrast was documented using a ROI with a standardized size of 70 mm², which was placed in the right and left main pulmonary artery, respectively. Average HU and standard deviation within the ROIs were documented. Overall image quality of each CTPA scan was evaluated based on imaging contrast and breathing artifacts using a five-point Likert scale (1. excellent contrast in all pulmonary vessels, no motion artifacts due to breathing; 2. good contrast in all pulmonary vessels, minimal motions artifacts due to breathing; 3. acceptable contrast in central and peripheral pulmonary vessels, sparse motions artifacts due to breathing in basal pulmonary segments; 4. Acceptable contrast in central and poor contrast in peripheral pulmonary vessels, moderate motion artifacts due to breathing in basal lung segments; 5. Poor contrast in central and unacceptable contrast in peripheral pulmonary vessels, distinct motion artifacts due to breathing in apical and basal lung segments).

Each pulmonary lung segment was separately evaluated for parenchymal abnormalities and pulmonary embolism. Parenchymal abnormalities were grouped in non-consolidating changes, including ground-glass opacities and/or crazy-paving pattern, and air space consolidation. No patient in the collective showed centrilobular nodules or parenchymal reticulation without underlying GGO (ground-glass opacification). Segmental parenchyma was defined by the dominating pattern as non-consolidating, consolidating, or, in case of an equal distribution of non-consolidating and consolidating changes, as mixed. Ground-glass opacification was defined as parenchyma with hazy increased attenuation without obscuration of underlying vessels. Crazy-paving was defined as ground-glass opacification with superimposed interlobular
3.6.1.). The unpaired two-samples Wilcoxon test was used to analyze the association of contrast enhancement in the main pulmonary arteries and image quality. Fisher's exact test was used for contingency table analysis. Significance level was set at \( p < 0.05 \). This retrospective study was approved by the ethics committee of the Albert Ludwig University of Freiburg (file number 234-20).

### 2.4. Statistical analysis and ethics

Statistical analysis was performed using dedicated software (R 3.6.1.). The unpaired two-samples Wilcoxon test was used to analyze the association of contrast enhancement in the main pulmonary arteries and image quality. Fisher's exact test was used for contingency table analysis. Significance level was set at \( p < 0.05 \). This retrospective study was approved by the ethics committee of the Albert Ludwig University of Freiburg (file number 234–20).

### 3. Results

#### 3.1. Patient selection and characteristics

| Characteristics                  | Whole population | PAT detected by CTPA | no PAT detected | p-value |
|----------------------------------|------------------|----------------------|-----------------|---------|
| number                           | 22 (100%)        | 9 (100%)             | 7 (100%)        | < 0.0001|
| age [years]                      | 60.4 ± 10.2      | 60.0 ± 8.7           | 65.0 ± 5.1      | 0.246   |
| female gender                    | 6 (27.3%)        | 4 (44.0%)            | 1 (14.3%)       | 0.222   |
| BMI [kg/m²]                      | 29.6 ± 6.4       | 27.7 ± 3.8           | 27.6 ± 3.4      | 0.986   |
| ICU-mortality                    | 10 (45.4%)       | 5 (55.5%)            | 3 (42.9%)       | 0.149   |
| ICU-stay (until date of submission) [days] | 23.2 ± 14.6 | 16.8 ± 12.8          | 37.3 ± 16.9     | 0.042   |
| TISS 10 - Score                  | 16.7 ± 7.2       | 16.0 ± 5.9           | 20.6 ± 7.4      | 0.816   |
| SAPS 2 - Score                   | 49.2 ± 13.9      | 51.6 ± 11.0          | 52.9 ± 10.8     | 0.190   |
| d-dimers (at time of CT-Scan) [mg/l FEU] | 14.2 ± 12.5 | 20.0 ± 15.3          | 9.0 ± 6.2       | 0.096   |
| d-dimers (at time of admission) [mg/l FEU] | 4.6 ± 4.9   | 6.5 ± 5.7            | 4.0 ± 2.6       | 0.312   |
| therapeutic anticoagulation (at time of admission) | 5 (22.7%) | 1 (4.5%)             | 3 (42.9%)       | 0.166   |
| fibrinogen (first value after ICU-admission) [mg/dl] | 601 ± 196 | 620 ± 190            | 558 ± 283       | 0.636   |
| blood glucose (at time of admission) [mg/dl] | 164 ± 60   | 136 ± 41             | 173 ± 38        | 0.269   |
| NIH-Alc [%]                      | 6.7 ± 0.4        | 6.2 ± 0.3            | 6.1 ± 0.5       | 0.804   |
| delay between positive SARS-CoV-2 PCR and CT-Scan [days] | 10.8 ± 10.3 | 7.4 ± 5.9            | 14.1 ± 12.9     | 0.189   |
| echocardiography: PAP sys. [mmHg] | 43.1 ± 16.1 | 48.7 ± 28.0          | 38.3 ± 8.9      | 0.188   |
| on venovenous ECMO-support       | 11 (50.0%)       | 5 (22.7%)            | 4 (57.1%)       | 0.953   |
| ECMO bloodflow (at time of CT-san) [l/min] | 3.9 ± 1.0 | 3.3 ± 0.64           | 4.1 ± 0.1       | 0.941   |
| pre-existing co-morbidities:     |                 |                      |                 |         |
| lung disorder                    | 3 (13.6%)        | 0 (0%)               | 2 (28.6%)       | 0.098   |
| tobacco smoke                    | 6 (27.3%)        | 1 (11.1%)            | 3 (42.9%)       | 0.166   |
| diabetes mellitus                | 5 (22.7%)        | 1 (11.1%)            | 1 (14.3%)       | 0.861   |
| arterial hypertension            | 9 (40.9%)        | 3 (33.3%)            | 3 (42.9%)       | 0.719   |
| heart failure                    | 5 (22.7%)        | 1 (11.1%)            | 3 (42.9%)       | 0.166   |
| chronic kidney failure           | 3 (13.6%)        | 1 (11.1%)            | 1 (14.3%)       | 0.860   |
| chronic liver failure            | 1 (4.5%)         | 0 (0%)               | 1 (14.3%)       | 0.271   |
| coagulopathy                     | 1 (4.5%)         | 1 (11.1%)            | 0 (0%)          | 0.396   |
| immunodeficiency                 | 5 (18.2%)        | 3 (33.3%)            | 0 (0%)          | 0.102   |
| obesity (BMI >30 kg/m²)          | 8 (36.4%)        | 2 (22.2%)            | 2 (28.6%)       | 0.789   |
|ObjectType.tiff                  |                 |                      |                 |         |

3.2. Segmental analysis of lung parenchyma changes in COVID-19

Analysis of lung parenchymal changes on segmental level per patient showed a minimum of 11 and a maximum of 19 lung segments to be affected with the predominant pattern of involvement being GGO/crazy-paving and air-space consolidation in 8/16 patients, respectively. In 11/16 patients, all lung segments showed parenchymal alterations consistent with SARS-CoV-2 pneumonia. In total, 113/283 (39.2%) lung segments showed GGO/crazy-paving and 103/283 (35.8%) showed consolidations as predominant pattern. A total of 50/288 (17.4%) lung segments showed GGO/crazy-paving and consolidated areas as mixed pattern and only 22/288 (7.6%) segments showed normal parenchyma, see Figs. 3 and 4.

#### 3.3. Pulmonary artery thrombosis

In 9 out of 16 patients, segmental and subsegmental pulmonary artery thrombi (PAT) were detected with a total of 40 segments affected in the whole cohort. In patients with PAT, an average of 4.44 ± 2.90 lung segments were affected (range 1–9). The analysis of distribution of PAT on lung lobe level, showed the right lower lobe to be affected in 7 out of 9 patients with PAT, followed by the right upper lobe which was affected in 6 out of 9 patients (see Fig. 2a).

PAT were detected in 17/113 (15.0%) segments with GGO/crazy-paving, in 16/103 (15.5%) segments with consolidations, and in 7/50 (14.0%) mixed segments. There was a significant association of pulmonary artery thrombosis with more severe parenchymal lung changes including more consolidations and less normal lung parenchyma (Chi² test, \( p = 0.006 \)), see Fig. 2b and Supplemental Table 2.
3.4. D-dimers

We did not observe an association between d-dimer level and number of affected segments in the patients with proven PAT (Pearson correlation coefficient $r = -0.05$, $p = 0.90$). There was a trend towards higher d-dimer levels in patients with PAT compared to those without, not reaching statistical significance ($20.03 \pm 15.33$ mg/l FEU versus $9.00 \pm 6.15$ mg/l, unpaired two-samples Wilcoxon test $P = 0.20$). However, all d-dimer levels $>20.00$ mg/l FEU were observed in patients with at least one segment with confirmed PAT (Fisher’s exact test $p = 0.08$).

4. Discussion

4.1. Pulmonary thrombosis

We found PAT in 9 out of 16 patients (56%) with COVID-19 undergoing contrast enhanced CTPA. This is a higher rate than previously reported, which may be biased by referral of the sickest patients to our ARDS/ECMO center. A study of 100 COVID-19 patients undergoing CTPA, pulmonary embolism was found in 25% [7]. Another study reported PAT in 18% of all patients [15]. A post mortem study of 12 autopsies however suggested PAT be the cause of death in 33% in
COVID-19 [10]. The authors also reported deep vein thrombosis in 58% [15]. Reports of lower rates of VTE in patients with COVID-19 compared to our cohort might be explained by different thresholds to perform diagnostic tests such as CTPA or different disease severities. In our cohort, 31% (5/16) patients required VV-ECMO compared to 8% in other studies [7]. The severity of COVID-19 pneumonia in our collective is also reflected by the fact, that only 8% of all lung segments evaluated by CT appeared to have unaffected parenchyma.

4.2. Pulmonary embolism or pulmonary artery thrombosis?

Several findings suggest the thrombi detected by CTPA in COVID-19 could – at least in part - be locally formed by the mechanism of thromboinflammation [16] SARS-CoV-2 is known to cause coagulopathy [8,17,18]. By mediating endothelial dysfunction and systemic inflammation, the coronavirus can cause a procoagulant state [19]. In addition, any acute respiratory distress syndrome (ARDS) can cause pulmonary thrombus formation. Endothelial damage will begin in the microvasculature and might extend as local process mediated by pro-inflammatory signals [20] Autopsy studies showed microthrombi in alveolar capillaries in 5/11 COVID-19 patients [21]. Also, thrombi are found much more frequently in the lungs than in any other organ [7,15]. The fact that PAT forms under prophylactic and systemic anti-coagulation might also strengthen the hypothesis of local clot formation [7,15]. There are case reports on PAT in SARS1 [22] which might suggest PAT to be a disease specific complication. We did not detect any thrombus in segments with normal parenchyma, supporting the hypothesis of pulmonary artery thrombosis. Taken together, we believe that most PAT developed locally. Additional embolism however cannot be excluded and deep vein thrombosis is also a frequent finding in severe COVID-19 [10]. Therefore, our and other available data combined support the hypothesis that pulmonary artery thrombi can originate locally. Since systemic embolism also remains a likely scenario, both mechanisms probably contribute to the full clinical picture.

4.3. Segmental changes in COVID-19 pneumonia

We found a significant heterogeneity in segmental changes in COVID-19. Our results are in line with studies describing GGO/crazy-paving and consolidations as predominant parenchyma changes and the postero-basal segment of the right lower lobe to be opacified most frequently in patients with COVID-19 pneumonia [23,24]. Long before the SARS-CoV-2 pandemic, studies using ventilation-perfusion-scintigraphy and autopsy as gold standard have shown PAT to be found most frequently in the right lower lobe. Our results demonstrate the same predominance of PAT for the right lower lobe. In our analysis the second most commonly involved lobe was the right upper lobe which is involved to a lesser degree in non-COVID-19 patients [25,26]. Analysis of the parenchymal changes demonstrated that the majority of patients showed involvement of all segments of the right upper lobe which is in line with the hypothesis of local vasculature damage due to COVID-19 pneumonia.

4.4. Image quality

Optimal imaging contrast in CTPA can be influenced by various factors. Sedation, artificial ventilation, altered cardiac output and ECMO systems are examples for patient factors in an ICU patient collective that challenge the ideal imaging contrast to the limit. Especially the analysis of the peripheral pulmonary vasculature can be compromised by consolidated lung parenchyma and altered circulation due to ECMO. Analyzing the association of vascular contrast intensity and subjective image quality we saw a tendency for lower subjective image quality when the measured mean HU in the main pulmonary arteries decreased. However, image quality was sufficient in all patients.

4.5. Limitations

Several limitations have to be considered when interpreting data presented here. First of all, we derived our data from a small patient collective. Since each individual segment was analyzed, a considerable number of segments could be registered. Still, data needs to be confirmed in a larger patient collective in order to prove a local clot formation. All patients were treated at a single medical intensive care unit. Decision to perform a CTPA was driven by judgement of the physicians in charge which could lead to an overestimation of rate of pulmonary artery thrombosis. Several factors, such as ventilation or ECMO, negatively influenced image quality of the CTPA examinations especially limiting the analysis of peripheral pulmonary vessels. Even though 16/22 patients underwent CTPA, a selection bias cannot be excluded. Since only ICU patients were included, we cannot extrapolate the findings to a collective of mild to moderate COVID-pneumonia. None of our patients had clinical evidence for a deep vein thrombosis. Still, we cannot exclude lower limb thromboembolism since lower limb venous duplex studies have not been routinely performed. We acknowledge the preliminary nature of these findings, including its retrospective nature and limited sample size. Data presented here has therefore be considered hypothesis generating only.

5. Conclusion

Thrombi in segmental pulmonary arteries are common in COVID-19. All Segments occluded by thrombus were opacitated and no pulmonary embolus was detectable located in a segment without opacitation. This might suggest local clot formation.

Ethics approval and consent to participate

The local ethics committee approved the study protocol (Ethik-Kommission der Albert-Ludwigs-Universität Freiburg im Breisgau 234/20). Available from the corresponding author on reasonable request.

Funding

The article processing charge was funded by the Baden-Wuerttemberg Ministry of Science, Research and Art and University of Freiburg in the funding program Open Access Publishing.

Availability of data and material

The datasets of this study are available from the corresponding author on reasonable request.

Permissions information

The authors declare that all illustrations and figures in the manuscript are entirely original and do not require reprint permission.

Consent for publication

We agree.

Code availability

Not applicable.

Declaration of competing interest

The authors declare that they have no conflicts of interests.
Acknowledgements

Not applicable.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.rmed.2020.106135.

Authors’ contribution

KMP concepted and designed the study, performed data acquisition, interpretation of the data, drafted and revised the manuscript. MB was a major contributor in analysis, interpretation of the statistics.

References

[1] D. Wang, B. Hu, C. Hu, et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China, J. Am. Med. Assoc. 323 (2020) 10616, https://doi.org/10.1001/jama.2020.1588.

[2] M. Chung, A. Bernheim, X. Mei, et al., CT imaging features of 2019 novel coronavirus (2019-nCoV), Radiology 295 (2020) 202–207, https://doi.org/10.1148/radiol.2020200230.

[3] J. Zhu, Z. Zhong, H. Li, et al., CT imaging features of 4121 patients with COVID-19: a meta-analysis, J Med Virol jmv 25910 (2020), https://doi.org/10.1002/jmv.25910.

[4] X. Ding, J. Xu, J. Zhou, Q. Long, Chest CT findings of COVID-19 pneumonia by duration of symptoms, Eur. J. Radiol. 127 (2020) 109009, https://doi.org/10.1016/j.ejrad.2020.109009.

[5] C. Shen, N. Yu, S. Cai, et al., Quantitative computed tomography analysis for stratifying the severity of Coronavirus Disease 2019, J. Pharmaceut. Biomed. Anal. 10 (2020) 123–129, https://doi.org/10.1016/j.jpba.2020.03.004.

[6] T. Ai, Z. Yang, H. Hou, et al., Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases, Radiology 296 (2020), https://doi.org/10.1148/radiol.2020200642, 200642.

[7] J. Helms, C. Tacquard, et al., Cricus Triggergroup Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis), High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study, Intensive Care Med. 46 (2020) 1089–1098, https://doi.org/10.1007/s00134-020-06062-x.

[8] N. Tang, D. Li, X. Wang, Z. Sun, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J. Thromb. Haemostasis 18 (2020) 844–847, https://doi.org/10.1111/jth.14768.

[9] J. Liljós, M. Leclerc, C. Chochois, et al., High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients, J Thromb Haemost jth (2020) 14869, https://doi.org/10.1111/jth.14869.

[10] D. Wichmann, J.-P. Sperhake, M. Lütgehetmann, et al., Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study, Ann. Intern. Med. 173 (2020), https://doi.org/10.7326/M20-2005.

[11] G.B. Danzi, M. Lofti, G. Galeazzi, E. Gherbesi, Acute pulmonary embolism and COVID-19 pneumonia: a random association? European Heart Journal eha254 41 (19) (2020) 1858, https://doi.org/10.1093/eurheartj/eha254.

[12] C. Magro, J.J. Mulvey, D. Berlin, et al., Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases, Transl. Res. 220 (2020) 1–13, https://doi.org/10.1016/j.trsl.2020.04.007.

[13] S.E. Rossi, J.J. Erasmus, M. Volpachico, et al., “Crazy-Paving” pattern at thin-section CT of the lungs: radiologic-pathologic overview, Radiographics 23 (2003) 1509–1519, https://doi.org/10.1148/rad.236035101.

[14] A.J.E. Moore, J. Wachsmuth, M.R. Chamarty, et al., Imaging of acute pulmonary embolism: an update, Cardiovasc. Diagn. Ther. 8 (2018) 225–243, https://doi.org/10.21037/cdt.2017.12.01.

[15] F.A. Klok, M.J.H.A. Kruip, N.J.M. van der Meer, et al., Incidence of Thrombotic Complications in Critically Ill ICU Patients with COVID-19, Thrombosis Research 189 (2020), 200463, https://doi.org/10.1016/j.thromres.2020.04.013.

[16] P.L.R. Nicolson, J.D. Welsh, A. Chauhan, et al., A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors, null 31 (2020) 685–690, https://doi.org/10.1007/s10593-019-00776-3.

[17] F. Zhou, T. Yu, R. Du, et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet 395 (2020) 1054–1062, https://doi.org/10.1016/S0140-6736(20)30566-3.

[18] T. Chen, D. Wu, H. Chen, et al., Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study, BMJ (2020) m1091, https://doi.org/10.1136/bmj.m1091.

[19] D. Giannisi, I.A. Ziozis, P. Gianni, Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past, J. Clin. Virol. 127 (2020) 104362, https://doi.org/10.1016/j.jcv.2020.104362.

[20] F. Ciceri, L. Beretta, A.M. Scandroglio, et al., Microvascular COVID-19 lung vessels obstructive thrombo inflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis, Crit Care Resusc 22 (2020) 95–97.

[21] T. Menter, J.D. Haslbauer, R. Nienhold, et al., Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction, Histopathology his 14134 (2020), https://doi.org/10.1111/his.14134.

[22] K.H.L. Ng, Pulmonary artery thrombosis in a patient with severe acute respiratory syndrome, Postgrad. Med. 81 (2005), https://doi.org/10.1136/pgmj.2004.030493 e3–e3.

[23] D.F. Worsley, C.K. Kim, A. Alavi, H.L. Palevsky, Detailed analysis of patients with matched ventilation-perfusion defects and chest radiographicopaques, J. Nucl. Med. 34 (1993) 1851–1853.

[24] A. Ro, N. Kageyama, T. Tanifuji, M. Sakuma, Autopsy-proven untreated previous pulmonary thromboembolism: frequency and distribution in the pulmonary artery and correlation with patients’ clinical characteristics: Previous untreated PE in cases of acute fatal PE, J. Thromb. Haemostasis 9 (2011) 922–927, https://doi.org/10.1111/j.1538-7836.2011.04225.x.

[25] A. Bernheim, X. Mei, M. Huang, et al., Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection, Radiology (2020) 200463, https://doi.org/10.1148/radiol.2020200463.

[26] J. Wu, X. Wu, W. Zeng, et al., Chest CT findings in patients with coronavirus disease 2019 and its relationship with clinical features, Invest. Radiol. 55 (2020) 257–261, https://doi.org/10.1097/RLI.0000000000000670.